Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEAGUL2: Lucentis Pharmacogenetics in Neovascular AMD
NCT01464723Phase 4Completed
- Sponsor
- University of California, San Diego
- Start
- May 2008
- Primary completion
- Dec 2011
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of ranibizumab in neovascular age-related macular degeneration (NVAMD), sponsored by University of California, San Diego. Started May 2008; status: completed.
02
Drugs
ranibizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT01464723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01464723.